Live feed07:00:00·14dPRReleasevia QuantisnowTakeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment ExpectationsByQuantisnow·Wall Street's wire, on your screen.TAK· Takeda Pharmaceutical Company LimitedHealth Care
